ADHD diagnosis and methylphenidate consumption in children and adolescents: A systematic analysis of health databases in France over the period 2010–2019
ContextADHD is the most common mental disorder in school-aged children. In France, methylphenidate is the only drug authorized for ADHD. Here, we describe the pattern of ADHD diagnosis and methylphenidate prescription to children and adolescents from 2010 to 2019.MethodsWe conducted a retrospective...
Main Authors: | Sébastien Ponnou, Benoît Thomé |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.957242/full |
Similar Items
-
A randomised controlled trial of combined EEG feedback and methylphenidate therapy for the treatment of ADHD
by: Li Li, et al.
Published: (2013-08-01) -
The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD
by: Rafał Bieś, et al.
Published: (2023-09-01) -
Atomoxetine and Methylphenidate Treatment in ADHD
by: Snircova E., et al.
Published: (2015-05-01) -
Potential Negative Effects of Dextromethorphan as an Add-On Therapy to Methylphenidate in Children With ADHD
by: Wei-Chen Chuang, et al.
Published: (2019-06-01) -
Methylphenidate does not restore the reduced serum BDNF levels in ADHD children
by: María-del-Carmen Augustin-Morales, et al.
Published: (2012-09-01)